Business Context and Reporting Period
This Form 8-K Current Report was filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on August 19, 2021, with the report date reflecting the earliest event reported. The registrant is a Delaware corporation headquartered in Palo Alto, California, and is classified as an emerging growth company. The filing primarily announces the entry into a material definitive agreement for a private placement offering.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of common stock and warrants.
- Securities Issued: 2,500,000 shares of Common Stock and warrants to purchase up to 2,500,000 shares.
- Purchase Price: $6.00 per share and accompanying warrant.
- Gross Proceeds: Approximately $15.0 million.
- Net Proceeds: Approximately $13,880,000 (after deducting placement agent fees and estimated offering expenses).
- Placement Agent Fee: 7% of aggregate gross proceeds paid to Maxim Group LLC.
- Warrant Terms: Exercise price of $7.50; immediately exercisable; 5-year term; subject to a 4.99% beneficial ownership limitation (increasable to 9.99% with consent).
- Use of Proceeds: General corporate purposes, primarily for pre-clinical and clinical development of product candidates, working capital, and capital expenditures.
Material Changes and Agreements
The filing details the execution of a Securities Purchase Agreement on August 19, 2021, with the offering closing on August 23, 2021. Key material changes include:
- Registration Rights: The Company agreed to file a registration statement by September 12, 2021, to register the resale of the shares and warrant shares, with effectiveness targeted by October 22, 2021.
- Issuance Restrictions: The Company agreed not to issue additional common stock or equivalents for 30 days after the registration statement becomes effective or 30 days after Rule 144 eligibility, with limited exceptions.
- Lock-Up Agreements: Directors and executive officers entered into lock-up agreements prohibiting the sale or disposition of securities for 60 days after the registration statement's effective date or until May 5, 2022, whichever is earlier.
Outlook, Risks, and Contingencies
Management intends to utilize the net proceeds to advance the clinical development of product candidates. The filing notes that the securities were sold in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D to accredited investors. The warrants are subject to customary anti-dilution adjustments for stock splits or dividends but are explicitly excluded from adjustments for subsequent equity issuances at prices lower than the exercise price. The filing incorporates by reference press releases dated August 19 and August 24, 2021, regarding the execution and closing of the offering.
Investor Verification Checklist
- Verify the actual closing date of the offering (August 23, 2021) and confirm receipt of net proceeds.
- Review the filed Registration Rights Agreement (Exhibit 10.3) to confirm the timeline for the registration statement effectiveness.
- Confirm the specific terms of the Warrants (Exhibit 4.1), particularly the exercise price of $7.50 and the 4.99% beneficial ownership limitation.
- Check subsequent filings to ensure the Company adhered to the 30-day issuance restriction following the registration statement's effectiveness.
- Validate the use of proceeds against future quarterly reports to ensure funds are allocated to clinical development as stated.